How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications

Eli D. Ehrenpreis, Arthur A. Ciociola, Prasad M. Kulkarni, Costas Kefalas, Alan Buchman, Carol Burke, Tedd Cain, Jason Connor, John Fang, Ronnie Fass, Joseph Phillips, Mark Pochapin, Paul Pockros, Philip Schoenfeld, Raj Vuppalanchi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Medication safety cannot be completely ensured after drugs enter the market. The FDA has developed the AERS for postmarketing drug surveillance for voluntary reporting of ADRs. Some medications used for gastrointestinal disease have received label changes or have been removed from the market. The FDA is developing new pharmacovigilance methods such as the Sentinel System to improve safety reporting. Health-care providers need to be aware of ADRs associated with the medications they prescribe. Participation in postmarketing surveillance programs will improve safety for our patients.

Original languageEnglish (US)
Pages (from-to)501-504
Number of pages4
JournalAmerican Journal of Gastroenterology
Volume107
Issue number4
DOIs
StatePublished - Apr 2012
Externally publishedYes

Fingerprint

Drug Labeling
Postmarketing Product Surveillance
Pharmacovigilance
Safety
Gastrointestinal Diseases
Patient Safety
Pharmaceutical Preparations
Health Personnel

ASJC Scopus subject areas

  • Gastroenterology

Cite this

How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications. / Ehrenpreis, Eli D.; Ciociola, Arthur A.; Kulkarni, Prasad M.; Kefalas, Costas; Buchman, Alan; Burke, Carol; Cain, Tedd; Connor, Jason; Fang, John; Fass, Ronnie; Phillips, Joseph; Pochapin, Mark; Pockros, Paul; Schoenfeld, Philip; Vuppalanchi, Raj.

In: American Journal of Gastroenterology, Vol. 107, No. 4, 04.2012, p. 501-504.

Research output: Contribution to journalArticle

Ehrenpreis, ED, Ciociola, AA, Kulkarni, PM, Kefalas, C, Buchman, A, Burke, C, Cain, T, Connor, J, Fang, J, Fass, R, Phillips, J, Pochapin, M, Pockros, P, Schoenfeld, P & Vuppalanchi, R 2012, 'How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications', American Journal of Gastroenterology, vol. 107, no. 4, pp. 501-504. https://doi.org/10.1038/ajg.2011.449
Ehrenpreis, Eli D. ; Ciociola, Arthur A. ; Kulkarni, Prasad M. ; Kefalas, Costas ; Buchman, Alan ; Burke, Carol ; Cain, Tedd ; Connor, Jason ; Fang, John ; Fass, Ronnie ; Phillips, Joseph ; Pochapin, Mark ; Pockros, Paul ; Schoenfeld, Philip ; Vuppalanchi, Raj. / How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications. In: American Journal of Gastroenterology. 2012 ; Vol. 107, No. 4. pp. 501-504.
@article{def841a937f948c287fa9a378cbb5e25,
title = "How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications",
abstract = "Medication safety cannot be completely ensured after drugs enter the market. The FDA has developed the AERS for postmarketing drug surveillance for voluntary reporting of ADRs. Some medications used for gastrointestinal disease have received label changes or have been removed from the market. The FDA is developing new pharmacovigilance methods such as the Sentinel System to improve safety reporting. Health-care providers need to be aware of ADRs associated with the medications they prescribe. Participation in postmarketing surveillance programs will improve safety for our patients.",
author = "Ehrenpreis, {Eli D.} and Ciociola, {Arthur A.} and Kulkarni, {Prasad M.} and Costas Kefalas and Alan Buchman and Carol Burke and Tedd Cain and Jason Connor and John Fang and Ronnie Fass and Joseph Phillips and Mark Pochapin and Paul Pockros and Philip Schoenfeld and Raj Vuppalanchi",
year = "2012",
month = "4",
doi = "10.1038/ajg.2011.449",
language = "English (US)",
volume = "107",
pages = "501--504",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications

AU - Ehrenpreis, Eli D.

AU - Ciociola, Arthur A.

AU - Kulkarni, Prasad M.

AU - Kefalas, Costas

AU - Buchman, Alan

AU - Burke, Carol

AU - Cain, Tedd

AU - Connor, Jason

AU - Fang, John

AU - Fass, Ronnie

AU - Phillips, Joseph

AU - Pochapin, Mark

AU - Pockros, Paul

AU - Schoenfeld, Philip

AU - Vuppalanchi, Raj

PY - 2012/4

Y1 - 2012/4

N2 - Medication safety cannot be completely ensured after drugs enter the market. The FDA has developed the AERS for postmarketing drug surveillance for voluntary reporting of ADRs. Some medications used for gastrointestinal disease have received label changes or have been removed from the market. The FDA is developing new pharmacovigilance methods such as the Sentinel System to improve safety reporting. Health-care providers need to be aware of ADRs associated with the medications they prescribe. Participation in postmarketing surveillance programs will improve safety for our patients.

AB - Medication safety cannot be completely ensured after drugs enter the market. The FDA has developed the AERS for postmarketing drug surveillance for voluntary reporting of ADRs. Some medications used for gastrointestinal disease have received label changes or have been removed from the market. The FDA is developing new pharmacovigilance methods such as the Sentinel System to improve safety reporting. Health-care providers need to be aware of ADRs associated with the medications they prescribe. Participation in postmarketing surveillance programs will improve safety for our patients.

UR - http://www.scopus.com/inward/record.url?scp=84859589065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859589065&partnerID=8YFLogxK

U2 - 10.1038/ajg.2011.449

DO - 10.1038/ajg.2011.449

M3 - Article

C2 - 22475958

AN - SCOPUS:84859589065

VL - 107

SP - 501

EP - 504

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 4

ER -